Literature DB >> 18192925

Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.

Lu-En Wai1, Masato Fujiki, Saori Takeda, Olivia M Martinez, Sheri M Krams.   

Abstract

Infiltration of natural killer (NK) cells into solid organ allografts is observed in clinical and experimental transplantation. Studies suggest a role for NK cells in acute and chronic rejection of solid organ allografts; however, the effects of immunosuppressive agents on NK cells are not clearly established. Rat NK cell lines were analyzed for proliferation and cytotoxicity in the presence of cyclosporine, FK506, or rapamycin. Lewis recipients of DA liver allografts received immunosuppressive agents after transplantation. NK cells demonstrated robust function both in the absence and presence of cyclosporine and FK506. In contrast, rapamycin significantly inhibited proliferation and cytotoxicity of NK cells. NK cell numbers remained stable in graft recipients treated with cyclosporine and FK506, whereas there was a significant decrease in NK cells in rapamycin-treated recipients. These data indicate that immunosuppressive drugs have differential effects on NK cell function that may impact the immune response of transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192925      PMCID: PMC4084728          DOI: 10.1097/01.tp.0000296817.28053.7b

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  25 in total

1.  Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice.

Authors:  S Maier; C Tertilt; N Chambron; K Gerauer; N Hüser; C D Heidecke; K Pfeffer
Journal:  Nat Med       Date:  2001-05       Impact factor: 53.440

Review 2.  The human natural cytotoxicity receptors (NCR) that induce HLA class I-independent NK cell triggering.

Authors:  C Bottino; R Biassoni; R Millo; L Moretta; A Moretta
Journal:  Hum Immunol       Date:  2000-01       Impact factor: 2.850

Review 3.  Innate immune responses to transplants: a significant variable with cadaver donors.

Authors:  W M Baldwin; C P Larsen; R L Fairchild
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

Review 4.  The changing role of natural killer cells in solid organ rejection and tolerance.

Authors:  William H Kitchens; Shuichiro Uehara; Catharine M Chase; Robert B Colvin; Paul S Russell; Joren C Madsen
Journal:  Transplantation       Date:  2006-03-27       Impact factor: 4.939

5.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  Rapamycin inhibits proliferation of Epstein-Barr virus-positive B-cell lymphomas through modulation of cell-cycle protein expression.

Authors:  Maria Vaysberg; Cynthia E Balatoni; Ronald R Nepomuceno; Sheri M Krams; Olivia M Martinez
Journal:  Transplantation       Date:  2007-04-27       Impact factor: 4.939

7.  Natural killer-cell activity after human renal transplantation in relation to killer immunoglobulin-like receptors and human leukocyte antigen mismatch.

Authors:  Maria Luisa Vampa; Paul J Norman; Lisa Burnapp; Robert W Vaughan; Steven H Sacks; Wilson Wong
Journal:  Transplantation       Date:  2003-10-27       Impact factor: 4.939

8.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.

Authors:  Thomas Decker; Susanne Hipp; Ingo Ringshausen; Christian Bogner; Madlene Oelsner; Folker Schneller; Christian Peschel
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

9.  Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas.

Authors:  Ronald R Nepomuceno; Cynthia E Balatoni; Yaso Natkunam; Andrew L Snow; Sheri M Krams; Olivia M Martinez
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

Review 10.  Turning on natural killer cells.

Authors:  L L Lanier
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

View more
  29 in total

1.  Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks.

Authors:  Jann N Sarkaria; Eva Galanis; Wenting Wu; Allan B Dietz; Timothy J Kaufmann; Michael P Gustafson; Paul D Brown; Joon H Uhm; Ravi D Rao; Laurence Doyle; Caterina Giannini; Kurt A Jaeckle; Jan C Buckner
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

Review 2.  Ras family of small GTPases in immunity and inflammation.

Authors:  Derek S Johnson; Youhai H Chen
Journal:  Curr Opin Pharmacol       Date:  2012-03-07       Impact factor: 5.547

3.  Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-08       Impact factor: 11.205

4.  Changes in natural killer cell subsets in pediatric liver transplant recipients.

Authors:  Betty Pham; Karine Piard-Ruster; Richard Silva; Amy Gallo; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Pediatr Transplant       Date:  2012-03

Review 5.  NK cells after transplantation: friend or foe.

Authors:  Uzi Hadad; Olivia Martinez; Sheri M Krams
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

6.  Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives.

Authors:  Lei Zhang; Zhe Gao; Chen Peng; Zheng-Yang Bin; Dan Zhao; Jing Wu; Qiang Xu; Jian-Xin Li
Journal:  Mol Divers       Date:  2012-08-14       Impact factor: 2.943

7.  Low incidence of severe cGvHD and late NRM in a phase II trial of thymoglobulin, tacrolimus and sirolimus for GvHD prevention.

Authors:  Z Al-Kadhimi; Z Gul; M Abidi; L G Lum; A Deol; W Chen; H Jang; C Ozust; A Langston; E Waller; J Uberti
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

8.  Renal transplant immunosuppression impairs natural killer cell function in vitro and in vivo.

Authors:  Olivier Morteau; Samkeliso Blundell; Aron Chakera; Sophia Bennett; Charita M Christou; Philip D Mason; Richard J Cornall; Christopher A O'Callaghan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

Review 9.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

10.  KIR-associated protection from CMV replication requires pre-existing immunity: a prospective study in solid organ transplant recipients.

Authors:  A Gonzalez; K Schmitter; H H Hirsch; C Garzoni; C van Delden; K Boggian; N J Mueller; C Berger; J Villard; O Manuel; P Meylan; M Stern; C Hess
Journal:  Genes Immun       Date:  2014-07-10       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.